search button
Open Access

Low serum albumin levels and high neutrophil counts are predictive of a poorer prognosis in patients with metastatic breast cancer

  • Authors:
    • Mengqi Xiang
    • Huachuan Zhang
    • Jinjun Tian
    • Yihang Yuan
    • Zhihua Xu
    • Jing Chen

  • View Affiliations

  • Published online on: October 19, 2022     https://doi.org/10.3892/ol.2022.13552
  • Article Number: 432

  • Copyright: © Xiang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Breast cancer is a severe disease with high incidence and mortality rates in menopausal women. Previous studies have shown that nutritional status and inflammation play a significant role in the development of breast cancer. However, whether serum albumin (ALB) and neutrophils (NE) accelerate the progression of this disease remains unclear. In the present study, a total of 94 cases of newly diagnosed metastatic breast cancer were assessed. For analysis, 26 risk factors including ALB and NE were assessed. Multivariate Cox proportional hazards regression analysis was then used to calculate the hazard ratios (HRs) and 95% confidence intervals (CIs) after adjusting for continuous and categorical covariates. Compared with the control group, patients with disease progression, low levels of ALB, higher NE, counts, and higher neutrophil to lymphocyte ratio counts were associated with worse overall survival (OS). When these risk factors were fitted into a multivariate regression model, progression [P<0.001, HR=3.03 (1.62‑5.66)], NE counts ≥3.370x109 [P=0.004, HR=2.15 (1.27‑3.65)] and ALB levels <43.275 g/l [P=0.008, HR=0.47 (0.27‑0.82)] remained statistically significant factors for a worse OS. These independently associated risk factors were used to form an OS estimation nomogram. The constructed nomogram demonstrated good accuracy in estimating risk, with a bootstrap‑corrected C index of 0.686. We further collected data on 30 patients for external validation and found the nomogram had an accuracy of 83.3%. In conclusion, low serum ALB levels and increased NE counts were predictive of a poorer prognosis in patients with metastatic breast cancer. Nomograms based on the multivariate analysis showed a good predictive ability for estimating the risk of OS.
View Figures
View References

Related Articles

Journal Cover

December-2022
Volume 24 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.5
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 5.7
  • CiteScore Rank: Q2: #139/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.574
  • SCImago Journal Rank (SJR): 0.644
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Xiang M, Zhang H, Tian J, Yuan Y, Xu Z and Chen J: Low serum albumin levels and high neutrophil counts are predictive of a poorer prognosis in patients with metastatic breast cancer. Oncol Lett 24: 432, 2022.
APA
Xiang, M., Zhang, H., Tian, J., Yuan, Y., Xu, Z., & Chen, J. (2022). Low serum albumin levels and high neutrophil counts are predictive of a poorer prognosis in patients with metastatic breast cancer. Oncology Letters, 24, 432. https://doi.org/10.3892/ol.2022.13552
MLA
Xiang, M., Zhang, H., Tian, J., Yuan, Y., Xu, Z., Chen, J."Low serum albumin levels and high neutrophil counts are predictive of a poorer prognosis in patients with metastatic breast cancer". Oncology Letters 24.6 (2022): 432.
Chicago
Xiang, M., Zhang, H., Tian, J., Yuan, Y., Xu, Z., Chen, J."Low serum albumin levels and high neutrophil counts are predictive of a poorer prognosis in patients with metastatic breast cancer". Oncology Letters 24, no. 6 (2022): 432. https://doi.org/10.3892/ol.2022.13552